CXCL13 and neoplasm: In a previous report, Shalapour et al.44 showed that OxP treatment increased CXCL13 levels in prostate cancer and recruited immunosuppressive plasma cells to the tumor, which would impede the T-cell-dependent immunogenic chemotherapy.